Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food and PPI Effect on Pirtobrutinib PK in Healthy Adults
NCT05134350Phase 1Completed
- Sponsor
- Loxo Oncology
- Start
- Feb 2020
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pirtobrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Loxo Oncology. Primary endpoints: Area Under the Concentration-time Curve From Hour 0 to 24, Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration and 6 more. Started Feb 2020; status: completed.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05134350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05134350.